Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

p53 hotspot mutants attenuate CTL-mediated tumor cell killing through a novel ALKBH5-YTHDF3-PD-L1 pathway

Zhuan Ju Xiang Zhang Wen-Jie Zuo Lu Zhang Xin Fan Chenxing Zhang Xiao-Fang Zhang Xiao Zhang Yidi Wang Ying Xing Bai-Le Zuo Ang-Ang Yang Rui Zhang Hui-Long Yin
Jul 2026 · Oncogene · Vol 45, pp. 3889 - 3903 · 0 citations · 48 references
Medicine

TL;DR

It is found that the oncogenic effect of mutant p53 in vivo is dependent on the tumor immune microenvironment, and restoration of ALKBH5 activation or inhibition of the m6A modification-YTHDF3 axis could potentially reactivate immune surveillance and eliminate tumors harboring mut-p53.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Sep 2026

Mutant p53 Gain-of-Function and Immune Suppression: Mathematical Modeling of STING-TBK1-IRF3 Axis Restoration for Enhanced Cancer Therapy.

Cancer progression is frequently driven by mutations in the tumor suppressor gene TP53. These mutations cause the protein to lose its normal growth-inhibitory functions and acquire new properties that promote tumor development and immune evasion. Recent experimental studies show that mutant p53 (mutp53) suppresses the...

Salaheldin Omer, R. Ouifki, Hermane Mambili-mamboundou · 0 citations
Review Open access Sep 2026

Opportunities in cancer gene therapy: inhibiting MDM2 and restoring p14ARF as a means to activate p53.

The MDM2/p53/p14ARF axis represents a central regulatory network controlling cell-cycle progression, genomic stability, and tumor suppression, and is frequently deregulated in human cancers. In many malignancies, particularly those retaining wild-type TP53, p53 activity is functionally suppressed through MDM2 overexpre...

S. B. de Oliveira, A. L. V. Alves, Bianca Naomi Niitsuma et al. · 0 citations
Open access Sep 2026

KDM4B-mediated AP2A1-K217 demethylation promotes immune evasion and anti-PD-1 therapy resistance in renal cell carcinoma

The role of non-histone lysine methylation in tumorigenesis has attracted increasing attention, and the dysregulated “writers”, “erasers” and “readers” of it are promising therapeutic targets. In this study, we demonstrated that lysine-specific demethylase 4B (KDM4B) was significantly upregulated in renal cell carc...

Zi-Ran Dai, Ming-Xiao Zhang, Hao Zhou et al. · 0 citations
Sep 2026

Targeting the PRMT5-CBX8 axis overcomes dual barriers of CD8⁺ T cell exclusion and tumor stemness for sensitizing TNBC to anti-PD-1 therapy

A novel epigenetic pathway orchestrated by PRMT5 that converges on the functional modulation of CBX8 to synchronously governs CD8⁺ T cell exclusion and tumor stemness is unveiled, nominating PRMT5 inhibition as a compelling therapeutic strategy for combination immunotherapy in TNBC.

Cong-Cong Chen, Yu-Heng Zhang, Chang Liu et al. · 0 citations
Sep 2026

Abstract B099: Tumor progression locus 2 kinase drives pancreatic cancer immune evasion through a MYBL2-CXCL10 signaling axis

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a chronically inflamed tumor microenvironment (TME) driven by persistent activation of innate inflammatory signaling. Tumor progression locus 2 (TPL2; MAP3K8) is a serine/threonine kinase downstream of KRAS that activates both MAPK and NF-κB signaling; howev...

Hua-Ping Li, Yu-Tong Geng, Hung-Han Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.